By Cocer Peptides 
1 ọnwa gara aga
Edemede na ozi ngwaahịa niile enyere na webụsaịtị a bụ naanị maka mgbasa ozi na ebumnuche mmụta.
Ngwaahịa ndị enyere na webụsaịtị a bụ naanị maka nyocha in vitro. A na-eme nyocha in vitro (Latin: * na iko *, nke pụtara na ihe eji enyo) na mpụga ahụ mmadụ. Ngwaahịa ndị a abụghị ọgwụ, ndị US Food and Drug Administration (FDA) akwadoghị ya, ha agaghịkwa eji ya gbochie, gwọọ, ma ọ bụ gwọọ ọnọdụ ahụike ọ bụla, ọrịa, ma ọ bụ ọrịa. Iwu amachibidoro nke ọma iwebata ngwaahịa ndị a n'ime ahụ mmadụ ma ọ bụ anụmanụ n'ụdị ọ bụla.
Ibu ibu aghọwo ihe na-esiwanye ike n'ihe gbasara ahụike ọha na eze n'ụwa nile, na-enwe ọtụtụ mmetụta dị njọ na ahụike anụ ahụ ndị mmadụ, dị ka ịkpalite ọrịa obi, ọrịa shuga, na ọrịa ndị ọzọ na-adịghị ala ala. N'afọ ndị na-adịbeghị anya, ọgwụ GLP-1 apụtala dị ka nhọrọ ọgwụgwọ na-ekwe nkwa na ngalaba nlekọta oke ibu.
Ọgụgụ 1 Usoro enwere ike ịbelata ibu nke GLP-1 kpatara. GI, eriri afọ; GLP-1, Glucagon-dị ka peptide-1; GLP-1R, Glucagon-dị ka peptide-1 nnabata.
Usoro nke Omume nke GLP-1 Ọgwụ na ọgwụgwọ oke ibu
GLP-1 bụ peptide endogenous nke sel L zoro ezo na sistemu endocrine nke eriri afọ. Ọgwụ GLP-1, nke a makwaara dị ka GLP-1 agonists receptor (GLP-1 RAs), na-eṅomi mmetụta physiological nke GLP-1 site na ịgbalite GLP-1 nnabata na ụzọ mgbama ya nke ala, si otú ahụ na-egosipụta mmetụta dị iche iche physiological nke na-enyere aka ịchịkwa ibu.
Na-akwalite mmepụta insulin: GLP-1 RA na-akpali mmepụta insulin site na mkpụrụ ndụ beta pancreatic n'ụzọ dabere na glucose. Mgbe ọkwa glucose ọbara na-ebili, GLP-1 RAs na-ejikọta na GLP-1 ndị na-anabata ya n'elu sel beta pancreatic, na-eme ka ụzọ mgbaàmà intracellular na-akwalite njikọ insulin na ntọhapụ, si otú ahụ na-ebelata ọkwa glucose ọbara. Ịkwụsị ọkwa glucose ọbara na-enyere aka ibelata njikọ abụba na nchekwa, na-egbochi mmụba agụụ na ịba ụba nke mgbanwe glucose ọbara kpatara.
Mbelata agụụ: GLP-1 RA na-arụ ọrụ na sistemu ụjọ nke etiti, ọkachasị mpaghara ụbụrụ jikọtara ya na njikwa agụụ, dị ka hypothalamus. Site na ijikọ ndị na-anabata GLP-1 n'elu neurons hypothalamic, ha na-achịkwa ntọhapụ neuropeptide, dị ka ibelata nzuzo nke peptides na-akpali agụụ na ịba ụba nke peptides na-ebelata agụụ, si otú ahụ na-akpali mmetụta nke njuju, ibelata iri nri, na nweta njikwa ibu.
Na-egbu oge mkpofu afọ: GLP-1 RA na-ebelata ọnụego nke ọdịnaya afọ na-abanye n'ime obere eriri afọ, na-agbatị oge nri na-adị n'ime afọ ma na-emepụta mmetụta nke afọ ojuju. Nke a na-egbu oge imefusị afọ ọ bụghị naanị na-ebelata oke nri kamakwa ọ na-eme ka ọ̀tụ̀tụ̀ glucose dị n'ọbara kwụsie ike, na-egbochi mmụkọ glucose ọbara mgbe nri gasịrị ma si otú a na-ebelata mkpokọta abụba.
Atụmatụ 1 Nchịkọta atụmatụ nke GLP-1 agonists ndị na-anabata ya: nhazi ọkwa, nchekwa ọgwụ na ịdị irè. GI, eriri afọ; GLP-1R, Glucagon-dị ka peptide-1 nnabata; PEG, polyethylene glycol.
Ngwa nke GLP-1 ọgwụ na ọgwụgwọ oke ibu
Ọgwụgwọ oke ibu okenye: Na ọgwụgwọ oke oke ibu, GLP-1 RA enwetala nsonaazụ dị egwu. Emechaala nnwale ụlọ ọgwụ nke Phase III nke semaglutide, yana nsonaazụ gosipụtara mmetụta mbelata ibu dị ukwuu. N'ime ọrụ STEP 2.4 mg / izu semaglutide, ndị ọrịa nwetara oke ibu dị arọ, na-akwadowanye ịdị irè nke GLP-1 RA na ọgwụgwọ oke ibu okenye. A na-ejikarị ọgwụ ndị a eme ihe dị ka akụkụ nke mmemme ịbelata oke ibu, yana njikwa nri na mmega ahụ na-agafeghị oke, iji nweta nsonaazụ ọnwụ arọ ka mma.
Ọgwụgwọ oke ibu nwata: Nnyocha e mere n'oge na-adịbeghị anya egosila na ejirila ọgwụ GLP-1 dị ka exenatide, semaglutide, na liraglutide na-agwọ ọnọdụ ndị metụtara oke ibu nwata, dị ka oke oke ibu, oke ibu metụtara polycystic ovary syndrome (PCOS), na oke ibu hypothalamic. Dịka ọmụmaatụ, ọmụmụ achọpụtala na ọgwụ ndị a nwere mmetụta ụfọdụ n'ịchịkwa oke ibu na ụmụaka, na-enyere aka melite paramita nke metabolic, na ịnye nhọrọ ọhụrụ maka ọgwụgwọ oke ibu nwata.
Ọgwụgwọ oke ibu maka ndị mmadụ pụrụ iche - Ndị ọrịa PCOS: Polycystic ovary syndrome (PCOS) bụ ọrịa endocrine a na-ahụkarị n'etiti ụmụ nwanyị na-amụ nwa, na oke ibu juru ebe niile n'etiti ndị ọrịa PCOS. GLP-1 RA nwere uru pụrụ iche n'ịgwọ oke ibu na ndị ọrịa PCOS. Nnyocha e mere egosiwo na ọgwụgwọ GLP-1 abụghị nanị na-ebelata ibu na ndị ọrịa PCOS kamakwa ọ na-eme ka nguzogide insulin dịkwuo elu, na-ebelata hyperandrogenism, na ọbụna na-abawanye ohere nke echiche okike na in vitro fatịlaịza. Nke a na-eme GLP-1 RA dị ka nhọrọ ọgwụgwọ na-ekwe nkwa nke ukwuu maka ndị ọrịa PCOS buru ibu, na-enye ụzọ ọhụrụ maka ịkwalite ahụike na ọmụmụ ha.
Mmechi
Na nchịkọta, ọgwụ GLP-1, dị ka ike na-apụta na ngalaba ọgwụgwọ oke ibu, na-egosipụta atụmanya ngwa na-ekwe nkwa na ọgwụgwọ oke ibu na ndị okenye, ụmụaka na ndị mmadụ pụrụ iche (dị ka ndị ọrịa PCOS) n'ihi usoro ha pụrụ iche. Site n'ọtụtụ ụzọ, gụnyere ịkwalite insulin secretion, na-egbochi agụụ, na igbu oge ịwụsị afọ, GLP-1 RA na-enyere ndị ọrịa aka n'ụzọ dị irè belata ibu ma melite ọnọdụ metabolic.
Na ọgwụgwọ oke ibu okenye, ọgwụ ndị dị ka liraglutide na semaglutide akwadoro site na nnwale ụlọ ọgwụ, na-enye nhọrọ ọgwụgwọ a pụrụ ịdabere na ya maka ndị ọrịa buru ibu. N'ịgwọ oke ibu na ndị ọrịa PCOS, GLP-1 RA ọ bụghị naanị na-enyere aka belata ibu kamakwa ọ na-emeziwanye ọrịa endocrine metụtara ọnọdụ ahụ, na-enye ọtụtụ uru maka ndị ọrịa PCOS.
Isi mmalite
[1] Zhang D, Lu H. GLP-1RA: Olileanya ọhụrụ na ọgwụgwọ oke ibu [J]. Akwụkwọ akụkọ nke Biosciences na ọgwụ, 2025,13 (2): 465-479. https://cstj.cqvip.com/Qikan/Article/Detail?id=HS727602025002035
[2] Kavarian PN, Mosher TL, Haija MA E. Iji glucagon-like-peptide 1 agonist receptor agonist na ọgwụgwọ oke ibu nwata. Echiche dị ugbu a na Ọgwụ ụmụaka, 2024,36 5:542-546. https://api.semanticscholar.org/CorpusID:272115519
[3] Wang JY, Wang QW, Yang XY, et al. Ndị na-anabata GLP-1 maka ọgwụgwọ oke ibu: Ọrụ dị ka ụzọ na-ekwe nkwa[J]. Ihu ihu na Endocrinology, 2023,14:1085799.DOI:10.3389/fendo.2023.1085799.
[4] Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 Agonist na-agwọ oke ibu ma gbochie ọrịa obi: Gịnị ka anyị rụzuru ugbu a?[J]. Akụkọ Atherosclerosis dị ugbu a, 2022,24(11):867-884.DOI:10.1007/s11883-022-01062-2.
[5] Baranowska-Bik A. Ọgwụgwọ oke ibu na ụmụ nwanyị nwere PCOS site na iji analogues GLP-1 - uru na oke. Endokrynologia Polska, 2022,73 (3): 627-643.DOI: 10.5603/EP.a2022.0047.
